Sharon K. Robertson

Sharon Robertson is a Partner at Cohen Milstein and a member of the Antitrust practice group. Ms. Robertson is also a member of the firm’s Executive Committee.

Ms. Robertson is a nationally recognized leader in complex, multi-district antitrust litigation, particularly in pharmaceutical antitrust class actions. In 2020 and 2021, Chambers USA named Ms. Robertson a “Top Ranked” lawyer in “Antitrust: Plaintiff – New York and the USA – Nationwide,” while Lawdragon has included her on its “500 Leading Lawyers in America” list annually since 2019. In 2019, The National Law Journal named her as one of nine “Elite Women of the Plaintiff's Bar,” an award that recognizes female lawyers who “have consistently excelled in high-stakes matters on behalf of plaintiffs over the course of their careers.” In the same year, Law360 named Ms. Robertson a “Life Sciences-MVP” for her “hard-earned successes” and “record-breaking deals.” In 2018, the American Antitrust Institute honored her with its prestigious “Outstanding Antitrust Litigation Achievement by a Young Lawyer” award for her role in securing one of the largest recoveries on behalf of end-payors in a federal generic suppression case in over a decade. Similarly, for five consecutive years, The Legal 500 has selected her as a “Next Generation Lawyer” (2017-2021), an honor bestowed upon only 10 lawyers under 40 years old across the country, who are positioned to become leaders in their respective fields. Likewise, The New York Law Journal recognized her as a Rising Star (2018) – one of only twenty individuals selected to receive an honor. In addition, Benchmark Litigation selected Ms. Robertson for inclusion on its “40 & Under Hot List” for four consecutive years (2018-2021) and Law360 named her as one of five “Rising Stars” (2018) in the field of competition law whose “professional accomplishments belie their age,” as did Super Lawyers (2014-2016). Ms. Robertson has also been recognized by Law360 as one of a few female litigators to secure leadership roles in high-profile MDLs, such as In re Lidoderm Antitrust Litigation (March 16, 2017).